Parecoxib and Imrecoxib Sequential Therapy: A Breakthrough in Managing Severe Acute Pancreatitis

Parecoxib and Imrecoxib Sequential Therapy: A Breakthrough in Managing Severe Acute Pancreatitis

This multicentre trial shows sequential use of COX-2 inhibitors parecoxib and imrecoxib significantly reduces severe acute pancreatitis (SAP) incidence, shortens organ failure duration, lowers local complications, and decreases 30-day mortality, with a good safety profile.
Antibiotic Exposure as a Major Risk Factor for Clostridioides difficile Infection: Evidence from a Large Israeli Cohort and Systematic Reviews

Antibiotic Exposure as a Major Risk Factor for Clostridioides difficile Infection: Evidence from a Large Israeli Cohort and Systematic Reviews

Recent research confirms that antibiotic exposure doubles the risk of hospital-onset Clostridioides difficile infection (CDI), especially in non-carriers, underscoring the central role of antibiotic stewardship and the need for additional preventive strategies in asymptomatic carriers.